Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

APOE: The New Frontier in the Development of a Therapeutic Target towards Precision Medicine in Late-Onset Alzheimer's.

Publication ,  Journal Article
Yang, A; Kantor, B; Chiba-Falek, O
Published in: Int J Mol Sci
January 27, 2021

Alzheimer's disease (AD) has a critical unmet medical need. The consensus around the amyloid cascade hypothesis has been guiding pre-clinical and clinical research to focus mainly on targeting beta-amyloid for treating AD. Nevertheless, the vast majority of the clinical trials have repeatedly failed, prompting the urgent need to refocus on other targets and shifting the paradigm of AD drug development towards precision medicine. One such emerging target is apolipoprotein E (APOE), identified nearly 30 years ago as one of the strongest and most reproduceable genetic risk factor for late-onset Alzheimer's disease (LOAD). An exploration of APOE as a new therapeutic culprit has produced some very encouraging results, proving that the protein holds promise in the context of LOAD therapies. Here, we review the strategies to target APOE based on state-of-the-art technologies such as antisense oligonucleotides, monoclonal antibodies, and gene/base editing. We discuss the potential of these initiatives in advancing the development of novel precision medicine therapies to LOAD.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Int J Mol Sci

DOI

EISSN

1422-0067

Publication Date

January 27, 2021

Volume

22

Issue

3

Location

Switzerland

Related Subject Headings

  • Precision Medicine
  • Molecular Targeted Therapy
  • Humans
  • Genetic Predisposition to Disease
  • Chemical Physics
  • Brain
  • Apolipoproteins E
  • Amyloid beta-Peptides
  • Alzheimer Disease
  • Age of Onset
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Yang, A., Kantor, B., & Chiba-Falek, O. (2021). APOE: The New Frontier in the Development of a Therapeutic Target towards Precision Medicine in Late-Onset Alzheimer's. Int J Mol Sci, 22(3). https://doi.org/10.3390/ijms22031244
Yang, Anna, Boris Kantor, and Ornit Chiba-Falek. “APOE: The New Frontier in the Development of a Therapeutic Target towards Precision Medicine in Late-Onset Alzheimer's.Int J Mol Sci 22, no. 3 (January 27, 2021). https://doi.org/10.3390/ijms22031244.
Yang, Anna, et al. “APOE: The New Frontier in the Development of a Therapeutic Target towards Precision Medicine in Late-Onset Alzheimer's.Int J Mol Sci, vol. 22, no. 3, Jan. 2021. Pubmed, doi:10.3390/ijms22031244.

Published In

Int J Mol Sci

DOI

EISSN

1422-0067

Publication Date

January 27, 2021

Volume

22

Issue

3

Location

Switzerland

Related Subject Headings

  • Precision Medicine
  • Molecular Targeted Therapy
  • Humans
  • Genetic Predisposition to Disease
  • Chemical Physics
  • Brain
  • Apolipoproteins E
  • Amyloid beta-Peptides
  • Alzheimer Disease
  • Age of Onset